ArticleMolecular psychiatry2026
A hierarchical multi-scale framework for schizophrenia: integrating symptom networks, functional circuits, and molecular pathways.
Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Schizophrenia is characterized by striking symptom heterogeneity, yet the mapping between specific clinical phenotypes and their underlying biological substrates remains elusive. To bridge this gap, we applied an integrative, multi-scale framework combining symptom network analysis, connectome-based predictive modeling (CPM), and transcriptomic mapping in a multi-center cohort of schizophrenia patients. This approach revealed a hierarchical dissociation between phenotypic topology and underlying biological mechanisms among the identified high-centrality core symptoms: Conceptual Disorganization, Unusual Thought Content, and Blunted Affect. While Conceptual Disorganization and Unusual Thought Content exhibited clinical coherence as psychosis-related features, CPM uncovered a divergence in their neural substrates. Conceptual Disorganization shared greater neurofunctional isomorphism with Blunted Affect-characterized by converging dysconnectivity within the Somatomotor Network (SMN) and subcortical circuits-whereas Unusual Thought Content displayed a distinct architecture driven by prominent Default Mode Network regulation beyond the shared sensorimotor substrate. Transcriptomic annotation further stratified these dimensions: psychosis-related networks were underpinned by synaptic regulatory genes, whereas Blunted Affect was enriched for intracellular MAPK signaling and metabolic processes. These findings delineate a hierarchical model in which distinct molecular etiologies-synaptic versus metabolic-cascade into shared systems-level failures at the "somato-cognitive interface". We conclude that while symptoms may group clinically, their treatment requires targeting separable molecular pathways that converge on common circuit bottlenecks. This framework reconciles symptom heterogeneity with overlapping biological substrates, advocating for a mechanism-based stratification of schizophrenia.
Indexed as
Identifiers
42218337What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.